Head-To-Head Comparison: Yumanity Therapeutics (NASDAQ:YMTX) and ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) and Yumanity Therapeutics (NASDAQ:YMTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Valuation & Earnings

This table compares ANI Pharmaceuticals and Yumanity Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $208.48 million 1.99 -$22.55 million $2.87 11.72
Yumanity Therapeutics $6.90 million 13.47 -$57.49 million ($21.57) -0.42

ANI Pharmaceuticals has higher revenue and earnings than Yumanity Therapeutics. Yumanity Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ANI Pharmaceuticals and Yumanity Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 0 1 0 3.00
Yumanity Therapeutics 0 0 3 0 3.00

ANI Pharmaceuticals currently has a consensus price target of $60.00, suggesting a potential upside of 78.41%. Yumanity Therapeutics has a consensus price target of $37.00, suggesting a potential upside of 306.15%. Given Yumanity Therapeutics’ higher probable upside, analysts clearly believe Yumanity Therapeutics is more favorable than ANI Pharmaceuticals.

Volatility and Risk

ANI Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Yumanity Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Institutional and Insider Ownership

58.9% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.0% of Yumanity Therapeutics shares are owned by institutional investors. 23.5% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Yumanity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ANI Pharmaceuticals and Yumanity Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals -7.25% 17.92% 7.60%
Yumanity Therapeutics N/A -125.46% -72.15%

Summary

ANI Pharmaceuticals beats Yumanity Therapeutics on 8 of the 13 factors compared between the two stocks.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.

Yumanity Therapeutics Company Profile

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.